Acute Medium Chain Triglycerides (MCT) Intake in Young and Older Participants
Opti-MCT
Optimisation of Acute Medium Chain Triglycerides Intake Characteristics on Different Plasma Metabolites in Young and Older Participants
1 other identifier
interventional
20
1 country
1
Brief Summary
Compare plasma metabolites following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young and older participants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 2, 2017
CompletedFirst Submitted
Initial submission to the registry
February 1, 2019
CompletedFirst Posted
Study publicly available on registry
February 5, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 25, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 25, 2019
CompletedMarch 25, 2020
March 1, 2020
2.1 years
February 1, 2019
March 24, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Concentration of plasma ketones (acetoacetate and B-hydroxybutyrate)
To compare acute ketonemia following different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol.
8 hours
Secondary Outcomes (3)
Concentration of plasma glucose
8 hours
Concentration of plasma insulin
8 hours
Concentration of plasma free fatty acids
8 hours
Study Arms (2)
MCT intake in young participants
EXPERIMENTALDifferent conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants. Interventions: 1. No MCT intake with breakfast, no lunch (i.e. CTL) 2. No MCT intake with lunch, no breakfast (i.e CTL inverted) 3. 10g of Betaquik with breakfast, no lunch (i.e BQ10) 4. 20g of Betaquik with breakfast, no lunch (i.e BQ20) 5. 10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC) 6. 10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)
MCT intake in older participants
EXPERIMENTALDifferent conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants. Interventions: 1. No MCT intake with breakfast, no lunch (i.e. CTL) 2. No MCT intake with lunch, no breakfast (i.e CTL inverted) 3. 10g of Betaquik with breakfast, no lunch (i.e BQ10) 4. 20g of Betaquik with breakfast, no lunch (i.e BQ20) 5. 10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC) 6. 10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)
Interventions
Water given with a regular standardize breakfast and water given at noon without lunch.
Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
Eligibility Criteria
You may qualify if:
- health young (20-40 y old) and 10 health older (\> 60 y old) participants
- Men and women
You may not qualify if:
- smoking
- diabetes (fasting glucose \>7.0 mmol/l and glycated hemoglobin \>6.9%)
- strenuous aerobic exercise more than three times a week
- untreated hypertension, dyslipidemia, and abnormal renal, liver, heart or thyroid function
- under medication known to affect triglycerides and carbohydrates metabolism (i.e. diuretics, beta-blockers, steroids, insulin sensitizing)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rearsh Centre on Aging
Sherbrooke, Quebec, J1H4C4, Canada
Related Publications (5)
Cunnane SC, Courchesne-Loyer A, St-Pierre V, Vandenberghe C, Pierotti T, Fortier M, Croteau E, Castellano CA. Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease. Ann N Y Acad Sci. 2016 Mar;1367(1):12-20. doi: 10.1111/nyas.12999. Epub 2016 Jan 14.
PMID: 26766547BACKGROUNDCroteau E, Castellano CA, Fortier M, Bocti C, Fulop T, Paquet N, Cunnane SC. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease. Exp Gerontol. 2018 Jul 1;107:18-26. doi: 10.1016/j.exger.2017.07.004. Epub 2017 Jul 12.
PMID: 28709938BACKGROUNDCourchesne-Loyer A, Croteau E, Castellano CA, St-Pierre V, Hennebelle M, Cunnane SC. Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. J Cereb Blood Flow Metab. 2017 Jul;37(7):2485-2493. doi: 10.1177/0271678X16669366. Epub 2016 Jan 1.
PMID: 27629100BACKGROUNDCourchesne-Loyer A, Fortier M, Tremblay-Mercier J, Chouinard-Watkins R, Roy M, Nugent S, Castellano CA, Cunnane SC. Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: estimated potential contribution to brain energy metabolism. Nutrition. 2013 Apr;29(4):635-40. doi: 10.1016/j.nut.2012.09.009. Epub 2012 Dec 28.
PMID: 23274095BACKGROUNDCastellano CA, Nugent S, Paquet N, Tremblay S, Bocti C, Lacombe G, Imbeault H, Turcotte E, Fulop T, Cunnane SC. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia. J Alzheimers Dis. 2015;43(4):1343-53. doi: 10.3233/JAD-141074.
PMID: 25147107BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 1, 2019
First Posted
February 5, 2019
Study Start
June 2, 2017
Primary Completion
June 25, 2019
Study Completion
June 25, 2019
Last Updated
March 25, 2020
Record last verified: 2020-03
Data Sharing
- IPD Sharing
- Will not share